Healthcare innovation

Department of Health – Abu Dhabi, MSD…

Department of Health – Abu Dhabi, MSD…

ABU DHABI, 15th June, 2022 (WAM) — The Department of Health – Abu Dhabi (DoH), today signed a declaration of collaboration with MSD GCC, a leading global biopharmaceutical company, in alignment with Abu Dhabi’s ongoing efforts to position itself as a global leader in life sciences and an incubator for healthcare innovation.

The agreement, which was signed at the BIO International Convention in San Diego, US, one of the premier life sciences events that brings together world leaders within the life sciences and biotechnology sectors, outlines key areas within which the two entities will work together to support the healthcare advancement and innovation in Abu Dhabi.

Both the DoH and MSD share a vision of improving the health and wellness of the people of the UAE, through broader access to innovative medicines and vaccines and other healthcare services. With this in mind, a delegation of the DoH headed by Sheikh Abdulla Al Hamed, Chairman of DoH, visited the MSD’s Research Discovery Hub in Boston with the objective of knowledge sharing, discussing future collaboration areas and strengthening relationships.

Dr. Asma Al Mannaei, Executive Director, Research Centre and Innovation, at the DoH said, “Under the directives of our wise leadership, Abu Dhabi is leading the transformation of the regional healthcare ecosystem by leveraging sciences and technology, reinforcing its position as a global leader in life sciences and an incubator for healthcare innovation. Through partnerships such as this, we can ensure our future initiatives and ongoing efforts will strengthen and further empower the emirate’s healthcare offering and ultimately improve the well-being of all members in our society.”

The first area for collaboration will look at scientific research and identifying ways to improve public health.

“Scientific research creates a strong foundation upon which we can strengthen our population health. The research will help us inform policies and programmes and boost our clinical research readiness level,” Al Mannaei added.

Collaborating to foster educational and capability-building partnerships ensures the provision of advanced medical education to support the highest standards of care. This will include continuing medical education programmes for healthcare professionals, as well as promoting patient and public healthcare education through teaching programs and awareness campaigns.

The third area for collaboration will focus on increasing the use of innovative technological and digital health solutions to provide the highest quality care outcome. Activities include exploring the use of digital technology, artificial intelligence and innovation for precision and personalised medicine to improve diagnosis and optimise the delivery of care.

Ashraf Mallak, Managing Director for MSD in the GCC, said, “The DoH has established one of the most innovative and sustainable healthcare systems in the world. We are also delighted to have hosted the DoH at the MSD Research Laboratories in Boston, the first visit of a UAE delegation to our research facilities. The DoH continues to increase access to innovative medicines and vaccines and supports the improvement of the health and wellness of the UAE’s people.”

Headed by Abdulla bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi (DoH), a high-profile Abu Dhabi delegation comprising government officials is visiting the US this month to expand and explore prospects of joint collaboration within the framework of healthcare at large and life science in specific.

The visit is expected to see meetings and agreement signings with leading partners to explore and activate collaborations in life science and real-world evidence, digital health, research and development, supply chain and many other areas.

The Abu Dhabi delegation had officials from ten critical entities in the life science ecosystem in Abu Dhabi, including the Department of Health – Abu Dhabi (DoH), Abu Dhabi Investment Office (ADIO), Mubadala Health, G42 Healthcare, Abu Dhabi Ports, ADQ, Etihad Cargo, Khalifa University, Hayat-vax and Pure Health.